

Review Article

Role of curcumin in Beta Thalassemia: A review

RUNNING TITLE: Effect of curcumin on β -Thalassemia

ABSTRACT:

Beta-thalassemia is an inherited blood disorder characterized by defective beta chains of hemoglobin which often lead to the development of anemia. These patients require periodic blood transfusions to compensate for anemia. However, these transfusions often lead to complications such as iron overload. This abnormal hemoglobin can lead to anemia and cause other medical problems. Curcumin which is a polyphenol has anti-inflammatory properties and also can increase the number of antioxidants in the body. The main aim of the study is to determine the efficiency of curcumin in the treatment of β -Thalassemia.

The administration of curcumin in the treatment of β -Thalassemia has aided to be beneficial. Curcumin also exhibited hepatoprotective properties as serum bilirubin decreased in the β -Thalassemia patients. Supplementation of curcumin is seen to improve insulin resistance, lipid profile, and systemic inflammation by reducing HOMA-IR, TG, TG/HDL ratio, and hs-CRP levels. Curcumin when used in the treatment for β -Thalassemia showed low or no side effects. It has powerful anti-inflammatory effects and acts as a potent antioxidant where it can neutralize the free radicals due to its chemical structure.

KEYWORDS: Curcumin, Curcuminoids, Beta-thalassemia, Antioxidants, Anti-inflammatory, innovation.

INTRODUCTION:

β -Thalassemia major is autosomal recessive anemia, which is characterized by defective β globin chain synthesis(1). It is responsible for up to 50% of severe cases of β -thalassemia worldwide. Patients often require blood transfusions to compensate for low oxygen levels in the blood. However, these blood transfusions are not free from post-transfusion complications such as iron overload. Iron overload results from increased absorption of iron in the gastrointestinal tract and is greatly exacerbated by frequent transfusion therapy (2). Patients with excessive iron often experience oxidative stress at intracellular and extracellular levels, leading to secondary complications such as anemia, hypercoagulability, hepatosplenomegaly, tissue injuries, and organ dysfunctions.

The primary treatment modality for iron overload in β -thalassemia major is iron chelation therapy(3,4) Iron chelating therapies are necessary for overall survival without complications(5). Several chelating drugs such as deferoxamine, deferiprone, or deferasirox were given daily to overcome the iron load. However, they are not free from adverse effects Besides, these are administered through a subcutaneous route which often results in poor adherence (6). Recently several studies were conducted to evaluate the efficacy of curcumin alone or in combination with iron-chelating drugs to overcome the iron load complications. Curcumin (diferuloylmethane) is the most important phenolic compound of turmeric, the common household spice (7). It is well known for its potential antioxidant, anti-inflammatory,

anticancer, and iron-chelator properties. Curcumin has an iron-chelating property and could exert its insulin-sensitizing action by reducing the iron deposition and oxidative stress in thalassemia patients. However, there are conflicting reports of its beneficial effects in β -thalassemia major. Besides, most RCTs were carried out in small patients with diverse profiles. These studies found no or limited evidence of the beneficial effects of curcumin in these patients. However, animal studies had reported positive findings. Our team has extensive knowledge and research experience that has translated into high-quality publications (8)(8,9)(8)(10–25). Considering the limited and contrasting findings on the effects of curcumin in patients with β -thalassemia major. The aim of the study is to review the effect of curcumin in these patients.

Comment [JR1]: Write full name of RCTs

Comment [JR2]: Delete t

Curcumin:

Curcumin, demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC) are collectively known as curcuminoids (26). These yellow-colored curcuminoids are isolated from *Curcuma longa* L. (turmeric) rhizomes, a plant species belonging to the Zingiberaceae family (27,28). Turmeric is a plant known for its medicinal use, dating back to 4000 years ago in the Vedic culture in India, where it was used as a culinary spice and had some religious significance.

The curcumin IUPAC name is (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta69 1,6-diene-3,5-dione, also having the following synonyms: 1,7-Bis(4-hydroxy-3- 70 methoxyphenyl)-1,6-heptadiene-3,5-dione or diferuloylmethane, CAS number: 458-37-7 71 (29), UNII: IT942ZTH98 , Drugbank id: DB11672 , Einecs: 207-280-5 and 72 PubChem CID: 969516 (30)

Comment [JR3]: Full name of IUPAC

Payton et al.(31) studied the typical representation of curcumin as a beta-diketone structure and confirms that it exhibits keto-enol tautomerism. As the main characteristics, this molecule has a molecular formula $C_{21}H_{20}O_6$, molecular weight: 368.385 g/mol, melting point: 179–182 °C, specific gravity: 0.9348 at 15 °C, a log Kow of 3.29 (est) and appears as orange-yellow needles/crystalline powder. Apart from these, curcumin has 1) a variable

solubility, i.e., insoluble in cold water and ether, soluble in alcohol and glacial acetic acid, and very soluble in ethanol and acetic acid; 2) good stability under recommended storage conditions (-20 °C); and 3) a hazardous decomposition process under fire conditions, leading to the formation of toxic products (carbon oxides). Almeida et al. (32) also reported the physicochemical properties of curcuminoids. Prasad et al. (33) reviewed the pharmacokinetic parameters of curcumin, namely those related to delivery, bioavailability, absorption, and metabolism. The main concern with respect to curcumin, when exploiting its biological activity, is its bioavailability due to poor solubility, coupled with its poor absorption in plasma and tissues, rapid metabolism, and excretion, despite acting as a potent acid-base and boron indicator. (34)

Efficacy of curcumin:

In the article done Pimpisid Koonyosying GTE-CUR drink promoted the uptake of plasma cholesterol through low-density-lipoprotein receptors-mediated endocytosis and also inhibited de novo synthesis of endogenous cholesterol synthesis in the liver. The GTE-CUR drink could only induce small changes in the hematopoietic activity indicators during the study. Curcumin also decreases the levels of serum NTBI in thalassemia subjects with iron Overload. It can also be noted that curcumin improved anemia and extramedullary hematopoiesis in the livers and spleens of tumor-bearing mice, which can also help in improving the quality and standard of human cancer patients(35).

In the study done by Ruchaneekorn Curcuminoids is a group of phenolic compounds of which are known for their antioxidant, anti-inflammatory, anti-cancer properties. It is said in this study that the mechanism of curcuminoids for scavenging free oxygen radicals and chelating NTBI is not known properly. The antioxidant property of curcumin shows that the percentage of MHb was significantly decreased, after administration of curcuminoids for 12 months, though there were no changes in Hb levels. It was also seen that the RBC GSH-Px activity gradually reduced during the treatment with curcuminoids and later returned to normal(36). In the study done by Elahe Mohammadi, it is seen there is only limited evidence for the effects of curcumin on excess iron in β -thalassemia patients. Curcumin is a plant polyphenol that exerts iron-binding activity. Curcumin also has a synergistic effect on the iron-chelating property of deferoxamine through an iron shuttle(37).

A study done by Esmat Nasserri suggests that large doses of curcumin administration did not have any serious adverse effects. It is seen that Curcumin alleviates oxidative stress through several mechanisms. The β -diketone moiety and the hydroxy/methoxy groups on phenyl rings in curcumin are responsible for the direct radical scavenging property(38). A study done by Jirawan Panachan reveals that antioxidant cocktails enhance their levels in beta-thalassemia patients' plasma. curcuminoids- and vitamin E cocktails significantly decreased iron-induced oxidative stress, increased Hb concentrations, and reduced hypercoagulability in β -thalassemia/Hb, also antioxidant cocktails improve anemia by the inhibitory effects of curcumin and glutathione on the complement system with unknown mechanism(39). A study by Ahmad Tamaddoni suggests that Curcumin has an iron-chelating property and also exerted insulin-sensitizing action by reducing the iron deposition and oxidative stress in thalassemic patients. Curcumin is used as adjuvant therapy for attenuation of metabolic complications(40).

Curcumin can be useful for the relief of metabolic complications in such patients. β -Thalassemia patients require repeated blood transfusions, which causes oxidative stress due to elevated levels of highly reactive compounds and lipid peroxides and the reduction in TAC. Iron overload, the main complication of β -thalassemia major, results from increased absorption of iron in the gastrointestinal tract and is greatly exacerbated by frequent transfusion therapy(2). Initially, the 12-week treatment plan with curcumin could not reduce Hb, serum iron, and ferritin levels. Previous animal research shows that for 6 months, dietary intervention with 0.2% curcumin in mice, iron level in liver and spleen decreased and mRNA of the L subunit of ferritin was down(41). Many therapeutic properties of curcumin such as antioxidant, anti-cancer, and anti-inflammatory activity have been confirmed previously(42).

Curcumin on plasma protein expression was investigated using proteomic analysis in patients compared to normal subjects and in patients before and after supplementing with 500 mg curcumin daily for 12 months. Plasma proteins involved in blood coagulation and hemostasis are prothrombin, fibrinogen, and haptoglobin. These were decreased in patients, particularly in splenectomized patients. The administration of curcumin led to a significant increase in prothrombin, fibrinogen, and haptoglobin. Curcumin provides a protective effect on copper toxicity in thalassemia intermedia patients. It also shows that curcumin regulates zinc

homeostasis which can be useful as a treatment method for patients with thalassemia intermedia, and especially in patients with zinc deficiency or low serum zinc/copper ratio(43).

Curcumin exhibits anti-inflammatory action through the suppression of numerous cell signaling pathways including NF- κ B, STAT3, Nrf2, ROS, and COX-2. Curcumin is a highly potent antimicrobial agent. It is also synergistic with other nutraceuticals such as resveratrol, piperine, catechins, quercetin, and genistein. (44). The pleiotropic activities of curcumin have been modulated by various signaling molecules such as pro-inflammatory cytokines, apoptotic proteins, cyclooxygenase-2, C-reactive protein, prostaglandin E2, prostate-specific antigen, adhesion molecules, phosphorylase kinase, AST, and ALT, and many other molecules in human participants(45). Extracts of green tea (GTE) and curcumin exhibit iron-chelating and antioxidant activities in iron-loaded cells and β -thalassemic mice (14). The function of iron chelators is to remove excess iron from the plasma and the cells by binding the labile and chelate iron, thus facilitating its excretion through the urine and feces. Deferoxamine was the first iron chelator to be used clinically and is given via subcutaneous route overnight infusion through a portable pump. Its side effects are minimal, but its mode of administration results in low compliance(46). Further studies are required to investigate the pathophysiological role of antioxidant cocktails which could improve the understanding of mechanisms and targets for the treatment of thalassemia.

This review shows that Curcumin is widely used in different parts of the world in the treatment of β -Thalassemia. Turmeric's bioactive ingredient is curcumin and the compounds related to curcumin. Curcumin and curcuminoids are excellent antioxidants. Antioxidants and iron chelators are found to be therapeutic in thalassemia. Curcumin administration in combination with deferoxamine has improved the antioxidant status in β -thalassemia major patients. They help to get rid of oxidative stress and excess iron. The easiest way to administer turmeric is the golden paste. This is a therapeutic version of dietary turmeric for the treatment of thalassemia.

CONCLUSION:

Current treatment plans for thalassemia include blood transfusions and folate supplements which show certain side effects. Curcumin is poorly absorbed into the bloodstream, but when curcumin was used in the treatment for β -Thalassemia it showed low or no side effects. Curcumin is a natural herbal supplement that is derived from *Curcuma longa*. Curcumin exhibited powerful anti-inflammatory effects and a very strong antioxidant. Curcumin supplements mainly contain piperine, which increases the effectiveness. It is a potent antioxidant where it can neutralize free radicals because of its chemical structure. It can also boost the activity of our body's antioxidant enzymes.

REFERENCE:

1. Mahmoud HM, Shoeib AA-SH, Abd El Ghany SM, Reda MM, Ragab IA. Study of alpha hemoglobin stabilizing protein expression in patients with β thalassemia and sickle cell anemia and its impact on clinical severity. *Blood Cells Mol Dis*. 2015 Dec;55(4):358–62.
2. Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. *Blood*. 2007 Jun 1;109(11):5027–35.
3. Timothy CN, Samyuktha PS, Brundha MP. Dental pulp Stem Cells in Regenerative Medicine--A Literature Review. *Research Journal of Pharmacy and Technology*. 2019;12(8):4052–6.
4. Brundha MP, Pathmashri VP, Sundari S. Quantitative Changes of Red Blood cells in Cancer Patients under Palliative Radiotherapy-A Retrospective Study. *Research Journal of Pharmacy and Technology*. 2019;12(2):687–92.
5. Harsha L, Brundha MP. Prevalence of Dental Developmental Anomalies among Men and Women and its Psychological Effect in a Given Population. *Journal of Pharmaceutical Sciences and Research; Cuddalore*. 2017 Jun 20;9(6):869–73.
6. Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. *Blood Transfus*. 2012 Oct;10(4):411–22.
7. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. *Diabetes Care*. 2012 Nov;35(11):2121–7.
8. Anita R, Paramasivam A, Priyadharsini JV, Chitra S. The m6A readers and aberrations associated with metastasis and predict poor prognosis in breast cancer patients. *Am J*

Cancer Res. 2020 Aug 1;10(8):2546–54.

9. Sinduja P, Ramani P, Gheena S, Ramasubramanian A. Expression of metallothionein in oral squamous cell carcinoma: A systematic review. *J Oral Maxillofac Pathol.* 2020 Jan;24(1):143–7.
10. Jayaseelan VP, Paramasivam A. Emerging role of NET inhibitors in cardiovascular diseases. *Hypertens Res.* 2020 Dec;43(12):1459–61.
11. Sharma N, Ojha H, Raghav P, Goyal RK. *Chemoinformatics and Bioinformatics in the Pharmaceutical Sciences.* Academic Press; 2021. 510 p.
12. Girija ASS, Smiline Girija AS. Delineating the Immuno-Dominant Antigenic Vaccine Peptides Against gacS-Sensor Kinase in *Acinetobacter baumannii*: An in silico Investigational Approach [Internet]. Vol. 11, *Frontiers in Microbiology.* 2020. Available from: <http://dx.doi.org/10.3389/fmicb.2020.02078>
13. Jaisankar AI, Smiline Girija AS, Gunasekaran S, Vijayashree Priyadharsini J. Molecular characterisation of csgA gene among ESBL strains of *A. baumannii* and targeting with essential oil compounds from *Azadirachta indica* [Internet]. Vol. 32, *Journal of King Saud University - Science.* 2020. p. 3380–7. Available from: <http://dx.doi.org/10.1016/j.jksus.2020.09.025>
14. Aggarwal BB, Surh Y-J, Shishodia S. *The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease.* Springer Science & Business Media; 2007. 490 p.
15. Jayaseelan VP, Ramesh A, Arumugam P. Breast cancer and DDT: putative interactions, associated gene alterations, and molecular pathways. *Environ Sci Pollut Res Int.* 2021 Jun;28(21):27162–73.
16. Arumugam P, George R, Jayaseelan VP. Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma. *Arch Oral Biol.* 2021 Feb;122:105030.
17. Kumar SP, Praveen Kumar S, Smiline Girija AS, Vijayashree Priyadharsini J. Targeting NM23-H1-mediated Inhibition of Tumour Metastasis in Viral Hepatitis with Bioactive Compounds from *Ganoderma lucidum*: A Computational Study [Internet]. Vol. 82, *Indian Journal of Pharmaceutical Sciences.* 2020. Available from: <http://dx.doi.org/10.36468/pharmaceutical-sciences.650>
18. Priyadharsini JV, Paramasivam A. RNA editors: key regulators of viral response in cancer patients. *Epigenomics.* 2021 Feb;13(3):165–7.
19. Mathivadani V, Smiline AS, Priyadharsini JV. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA-1) with *Murraya koenigii* bio-compounds: An in-silico approach. *Acta Virol.* 2020;64(1):93–9.
20. Girija As S, Priyadharsini J V, A P. Prevalence of and complex in elderly population with

urinary tract infection (UTI). *Acta Clin Belg.* 2021 Apr;76(2):106–12.

21. Anchana SR, Girija SAS, Gunasekaran S, Priyadharsini VJ. Detection of gene in carbapenem-resistant strains and targeting with biocompounds. *Iran J Basic Med Sci.* 2021 May;24(5):690–8.
22. Bogomolov V. *The Moment of Truth: A Novel and Two Stories.* 1982. 552 p.
23. Arvind P TR, Jain RK. Skeletally anchored forsus fatigue resistant device for correction of Class II malocclusions-A systematic review and meta-analysis. *Orthod Craniofac Res.* 2021 Feb;24(1):52–61.
24. Ramadurai N, Gurunathan D, Samuel AV, Subramanian E, Rodrigues SJL. Effectiveness of 2% Articaine as an anesthetic agent in children: randomized controlled trial. *Clin Oral Investig.* 2019 Sep;23(9):3543–50.
25. Mathew MG, Samuel SR, Soni AJ, Roopa KB. Evaluation of adhesion of *Streptococcus mutans*, plaque accumulation on zirconia and stainless steel crowns, and surrounding gingival inflammation in primary molars: randomized controlled trial. *Clin Oral Investig.* 2020 Sep;24(9):3275–80.
26. Majeed M, Badmaev V, Murray F. *Turmeric and the healing curcuminoids: Their amazing antioxidant properties and protective powers.* Keats Pub.; 1996.
27. Bhutya RK. *Ayurvedic Medicinal Plants of India (Vol. 1).* Scientific Publishers; 2011. 351 p.
28. Salehi B, Zucca P, Sharifi-Rad M, Pezzani R, Rajabi S, Setzer WN, et al. Phytotherapeutics in cancer invasion and metastasis. *Phytother Res.* 2018 Aug;32(8):1425–49.
29. Li S, Yuan W, Deng G, Wang P, Yang P, Aggarwal B. Chemical composition and product quality control of turmeric (*Curcuma longa* L.). 2011 [cited 2021 Oct 19]; Available from: https://scholarworks.sfasu.edu/agriculture_facultypubs/1/
30. Salehi B, Stojanović-Radić Z, Matejić J, Sharifi-Rad M, Anil Kumar NV, Martins N, et al. The therapeutic potential of curcumin: A review of clinical trials. *Eur J Med Chem.* 2019 Feb 1;163:527–45.
31. Payton F, Sandusky P, Alworth WL. NMR study of the solution structure of curcumin. *J Nat Prod.* 2007 Feb;70(2):143–6.
32. Péret-Almeida L, Cherubino APF, Alves RJ, Dufossé L, Glória MBA. Separation and determination of the physico-chemical characteristics of curcumin, demethoxycurcumin and bisdemethoxycurcumin. *Food Res Int.* 2005 Oct 1;38(8):1039–44.
33. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. *Cancer Res Treat.* 2014 Jan;46(1):2–18.

34. Larrañaga MD, Lewis RJ, Lewis RA. Hawley's Condensed Chemical Dictionary, Sixteenth Edition [Internet]. 2016. Available from: <http://dx.doi.org/10.1002/9781119312468>
35. Koonosying P, Tantiworawit A, Hantrakool S, Utama-Ang N, Cresswell M, Fucharoen S, et al. Consumption of a green tea extract-curcumin drink decreases blood urea nitrogen and redox iron in β -thalassemia patients. *Food Funct*. 2020 Jan 29;11(1):932–43.
36. Kalpravidh RW, Siritanaratkul N, Insain P, Charoensakdi R, Panichkul N, Hatairaktham S, et al. Improvement in oxidative stress and antioxidant parameters in β -thalassemia/Hb E patients treated with curcuminoids [Internet]. Vol. 43, *Clinical Biochemistry*. 2010. p. 424–9. Available from: <http://dx.doi.org/10.1016/j.clinbiochem.2009.10.057>
37. Mohammadi E, Tamaddoni A, Qujeq D, Nasseri E, Zayeri F, Zand H, et al. An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in β -thalassemia major patients: A double-blind randomized controlled clinical trial. *Phytother Res*. 2018 Sep;32(9):1828–35.
38. Nasseri E, Mohammadi E, Tamaddoni A, Qujeq D, Zayeri F, Zand H. Benefits of Curcumin Supplementation on Antioxidant Status in β -Thalassemia Major Patients: A Double-Blind Randomized Controlled Clinical Trial. *Ann Nutr Metab*. 2017 Sep 8;71(3-4):136–44.
39. Panachan J, Chokchaichamnankit D, Weeraphan C, Srisomsap C, Masaratana P, Hatairaktham S, et al. Differentially expressed plasma proteins of β -thalassemia/hemoglobin E patients in response to curcuminoids/vitamin E antioxidant cocktails [Internet]. Vol. 24, *Hematology*. 2019. p. 300–7. Available from: <http://dx.doi.org/10.1080/16078454.2019.1568354>
40. Aghamohammadi A, Abolhassani H, Rezaei N, Yazdani R. *Inborn Errors of Immunity: A Practical Guide*. Academic Press; 2021. 394 p.
41. Jiao Y, Wilkinson J 4th, Di X, Wang W, Hatcher H, Kock ND, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. *Blood*. 2009 Jan 8;113(2):462–9.
42. Trujillo J, Granados-Castro LF, Zazueta C, Andérica-Romero AC, Chirino YI, Pedraza-Chaverri J. Mitochondria as a Target in the Therapeutic Properties of Curcumin [Internet]. Vol. 347, *Archiv der Pharmazie*. 2014. p. 873–84. Available from: <http://dx.doi.org/10.1002/ardp.201400266>
43. Saeidnia M, Nowrouzi-Sohrabi P, Erfani M, Fazeli P, Tamaddon G, Karimi M. The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β -thalassemia intermedia: a randomized double-blind clinical trial. *Ann Hematol* [Internet]. 2021 Jan 12; Available from: <http://dx.doi.org/10.1007/s00277-021-04397-z>
44. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. *Br J Pharmacol*. 2017 Jun;174(11):1325–48.

45. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. *AAPS J.* 2013 Jan;15(1):195–218.
46. Voskou S, Aslan M, Fanis P, Phylactides M, Kleanthous M. Oxidative stress in β -thalassaemia and sickle cell disease. *Redox Biol.* 2015 Dec;6:226–39.

UNDER PEER REVIEW